AHA/ACC/ADA/ASN 2026: cardiovascular–kidney–metabolic (CKM) syndrome
International AHA/ACC/ADA/ASN Current
2026 AHA/ACC/ADA/ASN Guideline for the Management of Cardiovascular-Kidney-Metabolic Syndrome
Circulation. 2026;154:e50–e158
DOI 10.1161/CIR.0000000000001453 · Summary checked against the source: 2026-11
The first guideline for CKM syndrome: the links between obesity, diabetes, CKD and cardiovascular disease. It stages people from 0 to 4 and matches therapy to stage and to which conditions overlap.
At a glance
- Stage everyone by metabolic risk factors, eGFR (plus UACR from stage 2) and CVD. [1, B-NR · e58]
- Estimate risk with PREVENT (10-year CVD, ASCVD and HF, age 30–79; 30-year risk at 30–59). [1, B-NR · e67]
- Weight loss of at least 5–10% through lifestyle first. GLP-1-based therapy from stage 1 (BMI ≥27). [1, A · e75; 2a, A · e79]
- Type 2 diabetes with raised CV risk (PREVENT-CVD ≥7.5%): SGLT2i or GLP-1-based therapy, regardless of glucose. [1, A · e83]
- CKD: RASi (UACR ≥30) → SGLT2i (eGFR ≥20) → finerenone (T2D, UACR ≥30, eGFR ≥25) → GLP-1-based therapy (T2D, UACR ≥100). [e88]
- Pre-HF (stage 3): SGLT2i first if T2D or CKD. [1, B-NR · e93]
- Keep kidney-protective drugs going when eGFR falls below the starting threshold. [2a, B-R · e112]
Stages
| Stage | Definition |
|---|---|
| 0 | No risk factors: normal BMI and waist, glucose, BP and lipids; no CKD or CVD |
| 1: Excess or dysfunctional adiposity | BMI ≥25 (≥23 in Asians), waist ≥88/102 cm (women/men; ≥80/90 cm in Asians), or prediabetes (FPG 100–125 mg/dL, HbA1c 5.7–6.4%) |
| 2: Metabolic risk factors or CKD | Hypertension (≥130/80 or treated), TG ≥150, metabolic syndrome, type 2 diabetes, and/or moderate–high-risk CKD (KDIGO) |
| 3: Subclinical CVD | CAC ≥100 (or other subclinical atherosclerosis, low ABI); pre-HF (NT-proBNP ≥125, raised hs-troponin, or abnormal echo); or risk equivalents: very-high-risk CKD (G4–G5) or PREVENT-CVD ≥20% |
| 4: Clinical CVD | CHD, HF, stroke, PAD or AF with CKM risk factors. 4a no kidney failure; 4b kidney failure (eGFR <15 or dialysis) |
Adapted from AHA/ACC/ADA/ASN 2026 Table 4 [e61]
Monitoring
| Stage | Lipids, glucose, eGFR | BP | Other |
|---|---|---|---|
| 0 | Every 5 years | Yearly | BMI and waist yearly (all stages) |
| 1 | Every 2–3 years | Yearly | |
| 2 and above | Yearly (lipids, glucose) | Yearly | eGFR and UACR yearly |
Adapted from AHA/ACC/ADA/ASN 2026 longitudinal assessment recommendations [1, B-NR · e63]
- Social determinants of health: screen everyone with a validated tool. [1, B-NR · e65]
- Interdisciplinary care with a coordinator when ≥2 of diabetes, CKD and CVD coexist. [1, B-R · e70]
- PREVENT-HF ≥5%: check natriuretic peptides or troponin for pre-HF. [2a, B-NR · e59]
Obesity
| Recommendation | Grade |
|---|---|
| Lifestyle first: 5–10% weight loss (calorie restriction + activity); yearly counselling; multicomponent behavioural programmes | 1, A |
| Non-judgemental approach; long-term maintenance programmes | 1, B-NR |
| Stage 1 (BMI ≥27): GLP-1-based therapy with structured lifestyle | 2a, A |
| Metabolic and bariatric surgery for stages 1–3 not responding | 2a, A |
| Stage 4 with ASCVD, BMI ≥27: GLP-1-based therapy with proven CV benefit | 1, B-R |
| Stage 4 with ASCVD: naltrexone–bupropion or phentermine are harmful (raise BP and HR) | 3: Harm, B-R |
| Obesity with symptomatic HFpEF: GLP-1-based therapy | 1, A |
| GLP-1 therapy: reassess at 3–6 months; <5% weight loss = poor response | 1, B-NR |
Adapted from AHA/ACC/ADA/ASN 2026 [e75–e118]
Type 2 diabetes
- Stages 2–3: lifestyle plus intensified multifactorial treatment of glucose, BP, lipids and albuminuria. [1, A; 1, B-R · e83]
- PREVENT-CVD ≥7.5%: SGLT2i or GLP-1-based therapy with proven benefit. [1, A · e83]
- Metformin if HbA1c is 0.5–1% above goal on cardioprotective drugs. [2a, A · e83]
- Stage 4 with ASCVD: SGLT2i or GLP-1-based therapy; the combination can help. [1, A; 2a, C-LD · e100]
- Stage 4 with HF: SGLT2i first line; add GLP-1-based therapy in HFpEF. [1, A; 2a, B-R · e105–e106]
- After gestational diabetes: OGTT at 4–12 weeks postpartum; lifestyle or metformin if prediabetic. [1, B-R · e82]
CKD
flowchart TD
A["CKM stage 2–3 with CKD"] --> R["RASi at maximum tolerated dose<br/>T2D, or no T2D with UACR ≥30 · eGFR ≥30<br/>Class 1"]
A --> S["SGLT2i<br/>T2D, or no T2D with UACR ≥200 · eGFR ≥20<br/>Class 1 (UACR 30–199 without T2D: 2a)"]
R --> F{"T2D and UACR ≥30<br/>despite RASi + SGLT2i?"}
S --> F
F -->|"eGFR ≥25"| N["Add finerenone (nsMRA)<br/>Class 1"]
F -->|"UACR ≥100"| G["Add GLP-1-based therapy with<br/>proven kidney and CV benefit<br/>Class 1"]
Built from AHA/ACC/ADA/ASN 2026 CKD recommendations [e88]; see Figures 9–11 in the guideline.
- Recheck UACR 3–6 months after starting kidney-protective therapy; eGFR and potassium at 2–4 weeks after a RASi or MRA. [2a, B-R · e119]
- CKD with HFrEF: ARNI (or another RASi) if eGFR ≥30; SGLT2i for HF of any EF if eGFR ≥20. [1, A · e108]
Pre-HF and subclinical atherosclerosis
| Situation | Recommendation | Grade |
|---|---|---|
| Pre-HF | Intensive lifestyle and risk-factor control | 1, B-R |
| Pre-HF with T2D or CKD | SGLT2i first line | 1, B-NR |
| + diabetes, CKD, UACR ≥100 | Add GLP-1-based therapy | 2a, B-NR |
| + diabetes, CKD, UACR ≥30 | Add finerenone | 2a, B-NR |
| CAC >100 | Start or intensify preventive therapy | 2a, B-NR |
Adapted from AHA/ACC/ADA/ASN 2026 [e93]
Liver, sleep and pregnancy
- MASLD: FIB-4 every 1–2 years with diabetes or ≥2 risk factors (every 2–3 years with prediabetes). GLP-1-based therapy for MASLD with T2D, or MASH with significant fibrosis. [1, B-NR; 1, B-R · e113]
- Sleep apnoea: screen yearly with obesity; treat with weight management plus CPAP. [2a; 1, B-R · e115–e116]
- Pregnancy: HbA1c <6.5% before conception with diabetes; after an adverse pregnancy outcome (pre-eclampsia, gestational diabetes etc.), screen CKM risk factors within the first postpartum year and move to long-term primary care. [1 · e117]
Clinical pearls
- CKM stages 0–4: adiposity → metabolic risk or CKD → subclinical CVD → clinical CVD.
- Asian cut-offs: BMI ≥23, waist ≥80/90 cm.
- Stage 3 risk equivalents: CKD G4–G5 or PREVENT-CVD ≥20%.
- Kidney sequence: RASi → SGLT2i → finerenone → GLP-1 RA.
- Avoid naltrexone–bupropion and phentermine with established ASCVD.
Classes and levels of evidence
How AHA/ACC/ADA/ASN 2026 grades its recommendations. Adapted from AHA/ACC/ADA/ASN 2026 Table 2 [e55]. Hover over any class or level cited on this page to see what it means.
| Class | Strength | Meaning | Wording used |
|---|---|---|---|
| Class 1 | Strong | Benefit >>> risk | is recommended; is indicated, useful, effective or beneficial; should be performed or administered |
| Class 2a | Moderate | Benefit >> risk | is reasonable; can be useful, effective or beneficial |
| Class 2b | Weak | Benefit ≥ risk | may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain |
| Class 3: No benefit | Moderate | Benefit = risk (generally used only with level A or B) | is not recommended; is not indicated, useful or effective; should not be performed or administered |
| Class 3: Harm | Strong | Risk > benefit | potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered |
| Level | Meaning |
|---|---|
| Level A | High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies |
| Level B-R (randomised) | Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs |
| Level B-NR (non-randomised) | Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies |
| Level C-LD (limited data) | Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans |
| Level C-EO (expert opinion) | Consensus of expert opinion based on clinical experience |
Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.